<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2340-9894</journal-id>
<journal-title><![CDATA[Ars Pharmaceutica (Internet)]]></journal-title>
<abbrev-journal-title><![CDATA[Ars Pharm]]></abbrev-journal-title>
<issn>2340-9894</issn>
<publisher>
<publisher-name><![CDATA[Universidad de Granada]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2340-98942022000200173</article-id>
<article-id pub-id-type="doi">10.30827/ars.v63i2.23505</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Dolor lumbar persistente tras la administración de [131I]Iodo-6-&#946;-iodometil-19-norcolesterol: a propósito de un caso]]></article-title>
<article-title xml:lang="en"><![CDATA[Lower back pain after iodine-131-6-&#946;-iodomethyl-19-norcholesterol injection: a case report]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bonilla-Plaza]]></surname>
<given-names><![CDATA[Jaime Andrés]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[García-Ruiz]]></surname>
<given-names><![CDATA[María Hilda]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Baz-Sanz]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Azpeitia-Hernández]]></surname>
<given-names><![CDATA[Paz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castro-Velasco]]></surname>
<given-names><![CDATA[Rosa María]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pérez-Iruela]]></surname>
<given-names><![CDATA[Juan Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Ramón y Cajal Servicio de Medicina Nuclear ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital Universitario Ramón y Cajal Servicio de Radiofarmacia ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2022</year>
</pub-date>
<volume>63</volume>
<numero>2</numero>
<fpage>173</fpage>
<lpage>177</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2340-98942022000200173&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2340-98942022000200173&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2340-98942022000200173&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El [131I]Iodo-6-&#946;-iodometil-19-norcolesterol ([131I]Norcolesterol), radiofármaco indicado en el diagnóstico del estado funcional de tejido cortical suprarrenal, en la detección del tejido funcional en el hiperadrenocorticalismo así como en el aldosteronismo primario. Presentamos el caso de una mujer de 54 años de edad, remitida para la evaluación de una sospecha de aldosteronismo, y que inmediatamente después de la administración intravenosa de [131I]Norcolesterol sufrió una fuerte reacción adversa al medicamento, con mareo, rubor, aumento de la presión arterial, opresión en el pecho, dolor lumbar y sarpullido eritematoso hasta 9 días postinyección. Los síntomas se resolvieron satisfactoriamente tras la administración de antihistamínicos y corticoides. Se sospechó que esta reacción estuviera relacionada con la administración del [131I]Norcolesterol causada por una reacción alérgica de tipo I.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract The [131I]Iodine-6-&#946;-iodomethyl-19-norcholesterol ([131I]Norcholesterol; NP-59), is indicated in the diagnosis of the functional state of adrenal cortical tissue, in the detection of functional tissue in hyperadrenocorticalism as well as in primary aldosteronism. We present the case of a 54-year-old woman, referred for evaluation of suspected aldosteronism, and who immediately after intravenous administration of [131I]Norcholesterol suffered a strong adverse drug reaction, with dizziness, flushing, increased blood pressure, chest tightness, low back pain and erythematous rash up to 9 days after injection. Symptoms resolved satisfactorily after administration of antihistamines and corticosteroids. This reaction was suspected to be related to the administration of [131I]Norcholesterol caused by a type I allergic reaction.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[NP-59]]></kwd>
<kwd lng="es"><![CDATA[reacción adversa]]></kwd>
<kwd lng="es"><![CDATA[farmacovigilancia]]></kwd>
<kwd lng="en"><![CDATA[NP-59]]></kwd>
<kwd lng="en"><![CDATA[adverse drug reaction]]></kwd>
<kwd lng="en"><![CDATA[pharmacovigilance]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hesslewood]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Keeling]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Frequency of adverse reactions to radiopharmaceuticals in Europe]]></article-title>
<source><![CDATA[Eur J Nucl Med]]></source>
<year>1997</year>
<volume>24</volume>
<page-range>1179-82</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silberstein]]></surname>
<given-names><![CDATA[EB]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence of adverse reactions in nuclear medicine. Pharmacopeia Committee of the Society of Nuclear Medicine]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>1996</year>
<volume>37</volume>
<page-range>185-92</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kazerooni]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Sisson]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Shapiro]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Driedger]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hurwitz]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Mattar]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Petry]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic accuracy and pitfalls of [iodine-131]6-beta-iodomethyl-19-norcholesterol (NP-59) imaging]]></article-title>
<source><![CDATA[J Nucl Med]]></source>
<year>1990</year>
<volume>31</volume>
<page-range>526-34</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<source><![CDATA[Ficha Técnica norcolesterol iodado (131I)]]></source>
<year></year>
<publisher-name><![CDATA[Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Centro de Información de Medicamentos (CIMA)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maltby]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An adverse reaction to [131I]iodomethylnorcholesterol]]></article-title>
<source><![CDATA[Nucl Med Commun]]></source>
<year>2002</year>
<volume>23</volume>
<page-range>505-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spyridonidis]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Giannakenas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lakiotis]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Apostolopoulos]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse reactions following NP-59 administration]]></article-title>
<source><![CDATA[Nucl Med Commun]]></source>
<year>2008</year>
<volume>29</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>749-50</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>Subcommittee of Safety Issue for the Radiopharmaceuticals.Medical and Pharmaceutical Committee, Japan Radioisotope Association</collab>
<article-title xml:lang=""><![CDATA[The twenty-second report on survey of the adverse reaction to radiopharmaceuticals (the 25th survey in 1999)]]></article-title>
<source><![CDATA[Kaku Igaku]]></source>
<year>2001</year>
<volume>38</volume>
<page-range>139-50</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
